| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037831198 |
| P356 | DOI | 10.2165/00128072-199901040-00006 |
| P8608 | Fatcat ID | release_4zqsc7bnavgzpnv4fyhpkswaf4 |
| P698 | PubMed publication ID | 10935428 |
| P2093 | author name string | Jacobs RF | |
| Stowe CD | |||
| P2860 | cites work | The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis | Q33588660 |
| Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide | Q34312952 | ||
| Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention | Q34340511 | ||
| Low antituberculosis drug concentrations in patients with AIDS. | Q34735748 | ||
| Isoniazid liver injury during chemoprophylaxis in children | Q34986936 | ||
| Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction | Q36897388 | ||
| Disposition and metabolism of 14C-rifapentine in healthy volunteers | Q36897942 | ||
| Single-dose pharmacokinetics of rifapentine in elderly men. | Q36898025 | ||
| The treatment of tuberculosis in children | Q39830569 | ||
| Drug interactions with antibacterial agents. | Q40554611 | ||
| The clinical pharmacokinetics of rifabutin | Q41094407 | ||
| Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs | Q41160340 | ||
| Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status | Q41271542 | ||
| Pharmacogenetics in pediatrics. Implications for practice | Q41371110 | ||
| Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature | Q41688416 | ||
| Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans | Q42288254 | ||
| Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis | Q46472374 | ||
| Antituberculous agents. Isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide. | Q54499351 | ||
| RIFABUTIN | Q57953916 | ||
| Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents | Q64133863 | ||
| Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children | Q68799188 | ||
| Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs | Q69453088 | ||
| Pyridoxine deficiency in children treated with isoniazid | Q70086562 | ||
| A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months | Q70366665 | ||
| Hyperuricemia Due to Ethambutol | Q70372517 | ||
| Ethambutol in Tuberculous Meningitis | Q70388448 | ||
| Plasma concentrations of isoniazid in children with tuberculous infections | Q70773733 | ||
| Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis | Q70992665 | ||
| Hyperuricaemia induced by ethambutol | Q71095374 | ||
| Stability of pyrazinamide in two suspensions | Q71727362 | ||
| Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease | Q72078298 | ||
| Effect of preparation method and storage on rifampin concentration in suspensions | Q72397692 | ||
| Multiple-drug-resistant tuberculosis | Q72775262 | ||
| Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid | Q73047665 | ||
| Isoniazid acetylation metabolic ratio during maturation in children | Q73846460 | ||
| Rifampin and rifabutin and their metabolism by human liver esterases | Q73866054 | ||
| Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin | Q73949924 | ||
| Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis | Q74181416 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 299-312 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Treatment of tuberculous infection and disease in children: the North American perspective | |
| P478 | volume | 1 |
| Q36238439 | Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues | cites work | P2860 |
Search more.